KIAA0355 Inhibitors
KIAA0355 inhibitors encompass a variety of chemical compounds that impact cellular signaling pathways with potential effects on KIAA0355's activity. Staurosporine, as a broad-spectrum kinase inhibitor, can impede essential phosphorylation processes, which are pivotal for the functional conformation and subsequent activity of KIAA0355. Similarly, LY294002, a PI3K inhibitor, and Wortmannin, both dampen PI3K signaling, which could intersect with the pathways involving KIAA0355, leading to its inhibition. Rapamycin, targeting mTOR, disrupts a vital signaling axis that may regulate processes KIAA0355 is implicated in, thereby reducing its activity. PD98059 and U0126, both MEK inhibitors, have the potential to suppress MAPK/ERK signaling, which might be essential for KIAA0355's functional role, resulting in its decreased activity.
Other compounds in this group,such as SB203580, a p38 MAPK inhibitor, and SP600125, a JNK pathway inhibitor, can disrupt stress and cytokine signaling cascades that may modulate KIAA0355's activity. The functional inhibition of KIAA0355 can also stem from the action of PP2 and Dasatinib, which target Src family kinases, and Gefitinib, which inhibits EGFR tyrosine kinase. These inhibitors can interfere with the respective kinase-driven signaling pathways and indirectly lead to a decrease in KIAA0355's functional activity. Sorafenib further extends the range of action by targeting multiple kinases involved in various signaling pathways, which could intersect with those of KIAA0355 and result in its indirect inhibition. Each of these compounds has a distinct molecular target but converges on the premise that interfering with signaling pathways, either upstream or at points of intersection, can result in the diminished function of KIAA0355.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can inhibit a broad spectrum of kinases. It indirectly inhibits KIAA0355 by preventing phosphorylation processes that are crucial for KIAA0355's functional conformational state and activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it reduces the downstream signaling that may involve the activation of proteins that KIAA0355 interacts with, thereby reducing KIAA0355 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mechanistic target of rapamycin (mTOR), a key kinase that regulates cell growth and proliferation. Inhibition of mTOR can downregulate the pathways that KIAA0355 may be involved in, thus indirectly decreasing KIAA0355 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can reduce the ERK-mediated signaling that could intersect with KIAA0355 functional pathways, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK, which is involved in stress and cytokine signaling. Inhibiting p38 MAPK could disrupt pathways that modulate the activity of KIAA0355, potentially leading to its decreased activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a potent and selective MEK inhibitor that blocks the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 can prevent the activation of downstream targets and pathways that may include KIAA0355, resulting in its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in various cell signaling pathways. By inhibiting JNK, SP600125 may alter signaling cascades that regulate the activity of KIAA0355, leading to its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By targeting PI3K, it can disrupt downstream signaling pathways that are potentially linked with KIAA0355, thus indirectly leading to the inhibition of KIAA0355's function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 could interfere with signaling pathways that regulate the activity of KIAA0355, thereby inhibiting its function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted tyrosine kinase inhibitor, with activity against Src family kinases. By inhibiting these kinases, Dasatinib can modulate signaling pathways that KIAA0355 might be involved in, leading to its functional inhibition. | ||||||